• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

早期移植后因素可预测骨髓纤维化患者接受异基因造血细胞移植的生存结局。

Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis.

机构信息

Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA.

Hematologic Malignancies and Bone Marrow Transplantation Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

出版信息

Blood Cancer J. 2020 Mar 10;10(3):36. doi: 10.1038/s41408-020-0302-9.

DOI:10.1038/s41408-020-0302-9
PMID:32157091
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7064504/
Abstract

Factors predicting allogeneic hematopoietic cell transplantation (HCT) outcomes in myelofibrosis in the early post-HCT period have not been defined thus far. We attempt to study such factors that can help identify patients at a higher risk of relapse or death. This retrospective study included 79 patients who underwent first HCT for myelofibrosis at three centers between 2005 and 2016. Univariate analysis showed that red blood cell (RBC) transfusion dependence (HR 9.02, 95% CI 4.0-20.35), platelet transfusion dependence (HR 8.17, 95%CI 3.83-17.37), 100% donor chimerism in CD33 + cells (HR 0.21, 95%CI 0.07-0.62), unfavorable molecular status (HR 4.41, 95%CI 1.87-10.39), normal spleen size (HR 0.42, 95%CI 0.19-0.94), grade ≥ 2 bone marrow fibrosis (vs. grade ≤ 1; HR 2.7, 95%CI 1.1-6.93) and poor graft function (HR 2.6, 95%CI 1.22-5.53) at day +100 were statistically significantly associated with relapse-free survival (RFS). RBC transfusion dependence and unfavorable molecular status were also statistically significant in the multivariate analysis. Patients in whom both of these factors were present had a significantly worse RFS when compared to those with one or none. While limited by a small sample size, we demonstrate the significance of transfusion dependence and molecular status at day +100 in predicting outcomes.

摘要

在异基因造血细胞移植(HCT)后早期,预测骨髓纤维化患者 HCT 结局的因素尚未明确。我们试图研究有助于识别复发或死亡风险较高的患者的因素。本回顾性研究纳入了 2005 年至 2016 年间在三个中心接受首次骨髓纤维化 HCT 的 79 例患者。单因素分析显示,红细胞(RBC)输注依赖(HR 9.02,95%CI 4.0-20.35)、血小板输注依赖(HR 8.17,95%CI 3.83-17.37)、CD33+细胞 100%供者嵌合(HR 0.21,95%CI 0.07-0.62)、不良分子状态(HR 4.41,95%CI 1.87-10.39)、正常脾脏大小(HR 0.42,95%CI 0.19-0.94)、骨髓纤维化分级≥2 级(vs. 分级≤1;HR 2.7,95%CI 1.1-6.93)和移植物功能不良(HR 2.6,95%CI 1.22-5.53)与无复发生存(RFS)显著相关。在多因素分析中,RBC 输注依赖和不良分子状态也是显著相关的。与存在一个或没有这两个因素的患者相比,同时存在这两个因素的患者 RFS 显著更差。虽然受到样本量小的限制,但我们证明了第 100 天输血依赖和分子状态在预测结局方面的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b179/7064504/e4b43532e582/41408_2020_302_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b179/7064504/e2a3910dc857/41408_2020_302_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b179/7064504/e4b43532e582/41408_2020_302_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b179/7064504/e2a3910dc857/41408_2020_302_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b179/7064504/e4b43532e582/41408_2020_302_Fig2_HTML.jpg

相似文献

1
Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis.早期移植后因素可预测骨髓纤维化患者接受异基因造血细胞移植的生存结局。
Blood Cancer J. 2020 Mar 10;10(3):36. doi: 10.1038/s41408-020-0302-9.
2
Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis.比较用于骨髓纤维化患者造血干细胞移植的减低强度预处理方案。
Bone Marrow Transplant. 2019 Feb;54(2):204-211. doi: 10.1038/s41409-018-0226-1. Epub 2018 May 24.
3
Allogeneic hematopoietic cell transplantation for chronic myelofibrosis in Australia and New Zealand: older recipients receiving myeloablative conditioning at increased mortality risk.澳大利亚和新西兰的异基因造血细胞移植治疗慢性骨髓纤维化:接受清髓性预处理的老年受者死亡风险增加。
Biol Blood Marrow Transplant. 2012 Feb;18(2):302-8. doi: 10.1016/j.bbmt.2011.05.003. Epub 2011 May 11.
4
Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.晚期骨髓纤维化患者的异基因移植:脾肿大和高血清乳酸脱氢酶是成功植入的不良风险因素。
Clin Lymphoma Myeloma Leuk. 2016 May;16(5):297-303. doi: 10.1016/j.clml.2016.02.004. Epub 2016 Feb 18.
5
MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.MIPSS70+ v2.0 预测 Flu/Mel 预处理方案异基因造血干细胞移植后骨髓纤维化的长期生存。
Blood Adv. 2019 Jan 8;3(1):83-95. doi: 10.1182/bloodadvances.2018026658.
6
Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis.骨髓纤维化异基因造血干细胞移植的回顾性研究。
Bone Marrow Transplant. 2011 Apr;46(4):557-61. doi: 10.1038/bmt.2010.276. Epub 2010 Nov 1.
7
Allogeneic hematopoietic stem cell transplantation for myelofibrosis.异基因造血干细胞移植治疗骨髓纤维化
Blood. 2003 Dec 1;102(12):3912-8. doi: 10.1182/blood-2003-06-1856. Epub 2003 Aug 14.
8
Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.单倍体与同胞相合供者在成人急性淋巴细胞白血病造血干细胞移植中的结局:欧洲血液和骨髓移植学会急性白血病工作组的一项研究。
J Hematol Oncol. 2021 Apr 1;14(1):53. doi: 10.1186/s13045-021-01065-7.
9
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.异基因反应性作为血液系统恶性肿瘤治疗的治疗原则。非清髓性预处理的异基因造血细胞移植的临床和免疫学方面的研究。
Dan Med Bull. 2007 May;54(2):112-39.
10
Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation.家族间不相合异基因造血干细胞移植治疗骨髓纤维化:欧洲血液和骨髓移植学会慢性恶性肿瘤工作组报告。
Biol Blood Marrow Transplant. 2019 Mar;25(3):522-528. doi: 10.1016/j.bbmt.2018.10.017. Epub 2018 Nov 5.

引用本文的文献

1
A comparison of haploidentical versus HLA-identical sibling outpatient hematopoietic cell transplantation using reduced intensity conditioning in patients with acute leukemia.比较亲缘单倍体与 HLA 同型相匹配同胞供者在急性白血病患者中采用减低强度预处理方案的门诊造血细胞移植。
Front Immunol. 2024 Oct 4;15:1400610. doi: 10.3389/fimmu.2024.1400610. eCollection 2024.
2
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.骨髓纤维化患者接受莫洛替尼或芦可替尼治疗期间,骨髓纤维化的变化与疗效结果无关。
EJHaem. 2024 Feb 5;5(1):105-116. doi: 10.1002/jha2.854. eCollection 2024 Feb.
3

本文引用的文献

1
Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation.异基因干细胞移植后混合髓系嵌合体与骨髓纤维化复发
Haematologica. 2021 Jul 1;106(7):1988-1990. doi: 10.3324/haematol.2019.223503.
2
Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis.异基因造血细胞移植治疗骨髓纤维化的长期结果。
Haematologica. 2019 Sep;104(9):1782-1788. doi: 10.3324/haematol.2018.205211. Epub 2019 Feb 7.
3
Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis.
Characterization of engraftment dynamics in myelofibrosis after allogeneic hematopoietic cell transplantation including novel conditioning schemes.
异基因造血细胞移植后骨髓纤维化中植入动力学的特征,包括新型预处理方案。
Front Oncol. 2023 Aug 10;13:1205387. doi: 10.3389/fonc.2023.1205387. eCollection 2023.
4
Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis.创新策略改善骨髓纤维化患者造血干细胞移植的结局。
Am J Hematol. 2022 Nov;97(11):1464-1477. doi: 10.1002/ajh.26654. Epub 2022 Jul 19.
5
Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis.异基因造血干细胞移植预处理方案为非清髓性预处理联合环磷酰胺预防移植物抗宿主病在骨髓纤维化患者中的应用
Transplant Cell Ther. 2022 May;28(5):259.e1-259.e11. doi: 10.1016/j.jtct.2022.02.004. Epub 2022 Feb 11.
6
Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study.异基因血液或骨髓移植联合亲缘单倍体供者和移植后环磷酰胺治疗骨髓纤维化:一项多中心研究。
Leukemia. 2022 Mar;36(3):856-864. doi: 10.1038/s41375-021-01449-1. Epub 2021 Oct 18.
7
Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party.异基因造血细胞移植治疗骨髓纤维化:EBMT 慢性恶性肿瘤工作组关于移植物失败、移植物功能不良和复发的定义和管理策略建议:最佳实践推荐。
Leukemia. 2021 Sep;35(9):2445-2459. doi: 10.1038/s41375-021-01294-2. Epub 2021 May 26.
8
Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies.阐明慢性骨髓增生性恶性肿瘤的新生物学方面和潜在的新治疗方法。
Hematol Oncol. 2020 Dec;38(5):654-664. doi: 10.1002/hon.2771. Epub 2020 Sep 4.
高风险分子突变对骨髓纤维化患者移植结局的影响。
Biol Blood Marrow Transplant. 2019 Jun;25(6):1142-1151. doi: 10.1016/j.bbmt.2019.01.002. Epub 2019 Jan 6.
4
Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis.比较用于骨髓纤维化患者造血干细胞移植的减低强度预处理方案。
Bone Marrow Transplant. 2019 Feb;54(2):204-211. doi: 10.1038/s41409-018-0226-1. Epub 2018 May 24.
5
Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation.分子遗传学对异基因造血干细胞移植后骨髓纤维化患者预后的影响
Biol Blood Marrow Transplant. 2017 Jul;23(7):1095-1101. doi: 10.1016/j.bbmt.2017.03.034. Epub 2017 Apr 4.
6
Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis.骨髓纤维化患者接受移植时基于减低剂量预处理方案的移植后结局
Biol Blood Marrow Transplant. 2016 Jul;22(7):1206-1211. doi: 10.1016/j.bbmt.2016.02.019. Epub 2016 Mar 10.
7
MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.MPD-RC 101:骨髓纤维化患者减低强度异基因造血干细胞移植的前瞻性研究
Blood. 2014 Aug 14;124(7):1183-91. doi: 10.1182/blood-2014-04-572545. Epub 2014 Jun 24.
8
Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis.骨髓纤维化消退的动态变化可预测骨髓纤维化患者异基因干细胞移植后的生存情况。
Biol Blood Marrow Transplant. 2014 Jun;20(6):812-5. doi: 10.1016/j.bbmt.2014.02.019. Epub 2014 Mar 1.
9
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.伴有未突变 JAK2 的骨髓增殖性肿瘤中的体细胞 CALR 突变。
N Engl J Med. 2013 Dec 19;369(25):2391-2405. doi: 10.1056/NEJMoa1312542. Epub 2013 Dec 10.
10
Somatic mutations of calreticulin in myeloproliferative neoplasms.髓系增殖性肿瘤中的钙网织蛋白体细胞突变。
N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10.